골반장기탈출(POP) 치료 및 관리/골반장기탈출 시장 규모 조사와 예측 : 제품별, 치료법별, 용도별, 최종사용자별, 지역별 예측(2025-2035년)

Market Definition, Recent Developments & Industry Trends

The POP treatment and management market encompasses medical devices, surgical interventions, and conservative therapies aimed at addressing pelvic organ prolapse (POP), a condition characterized by the descent of pelvic organs due to weakened pelvic floor muscles and connective tissues. The market includes manufacturers of synthetic mesh, sutures, pessaries, and robotic surgical systems, alongside healthcare providers offering surgical and non-surgical management such as pelvic floor muscle training (PFMT). Key ecosystem participants include hospitals, ambulatory surgical centers (ASCs), gynecologists, urologists, physical therapists, and medical device innovators.

In recent years, the market has evolved in response to regulatory scrutiny surrounding transvaginal mesh products, prompting shifts toward safer surgical techniques, improved biomaterials, and minimally invasive approaches. Robotic-assisted surgeries are gaining clinical acceptance due to enhanced precision and reduced recovery times. Concurrently, there is increasing emphasis on conservative management strategies, including PFMT, reflecting patient preference for non-invasive treatment options. Aging female populations, greater awareness of pelvic health, and improvements in surgical technologies are expected to support steady growth over the 2025-2035 forecast period.

Key Findings of the Report

• Market Size (2024): USD 0.72 billion
• Estimated Market Size (2035): USD 1.45 billion
• CAGR (2025-2035): 6.60%
• Leading Regional Market: North America
• Leading Segment: Surgical treatment under Treatment segment

Market Determinants

Rising Prevalence of Pelvic Floor Disorders

An aging global female population, combined with risk factors such as childbirth, obesity, and hysterectomy procedures, is contributing to increased incidence of pelvic organ prolapse. The growing patient pool directly supports demand for both surgical and non-surgical management solutions, reinforcing steady procedural volumes.

Technological Advancements in Minimally Invasive Surgery

The adoption of robotic systems and advanced suturing techniques has enhanced surgical precision and reduced complication rates. These technological improvements increase patient confidence and physician adoption, thereby expanding procedural uptake in hospitals and ASCs.

Regulatory Oversight and Safety Concerns

Heightened regulatory scrutiny, particularly concerning synthetic mesh implants, has reshaped the competitive landscape. While this has constrained certain product segments, it has also stimulated innovation in safer materials and alternative repair techniques, strengthening long-term product development pipelines.

Growing Acceptance of Conservative Therapies

Pelvic floor muscle training (PFMT) and pessary usage are gaining traction as first-line treatment approaches for mild to moderate cases. The preference for non-invasive management options reflects broader patient-centric care trends and reduces immediate surgical burden, although it may moderate short-term device revenues.

Healthcare Infrastructure and Reimbursement Dynamics

Access to specialized gynecological and urogynecological services, along with reimbursement policies, significantly influences treatment adoption. Favorable reimbursement frameworks in developed regions support surgical interventions, whereas limited coverage in certain markets may constrain growth.

Opportunity Mapping Based on Market Trends

Robotic-Assisted Surgical Expansion

Advancements in robotic systems present significant growth opportunities.

• Integration of advanced imaging and navigation systems
• Expansion of robotic capabilities into gynecological reconstructive procedures
• Increased adoption within ASCs

These developments enhance surgical outcomes and support premium pricing models.

Next-Generation Biomaterials and Mesh Alternatives

Innovation in biocompatible materials is reshaping product development.

• Development of absorbable or hybrid meshes
• Improved suture materials for native tissue repair
• Reduced risk of erosion and complications

Safer material innovation can rebuild clinical trust and expand adoption.

Conservative Therapy Integration

Integration of PFMT programs into digital health platforms creates scalable non-invasive treatment pathways.

• Remote physiotherapy monitoring
• App-based pelvic floor training solutions
• Hybrid care models combining therapy and surgery

Such approaches broaden patient engagement and long-term care continuity.

Expansion in Ambulatory Surgical Centers

ASCs are emerging as cost-efficient alternatives for minimally invasive POP procedures.

• Reduced inpatient costs
• Faster patient turnover
• Enhanced accessibility

Shifting procedural volumes toward ASCs may improve system-wide cost efficiency and market penetration.

Key Market Segments

By Product:

• Synthetic Mesh
• Sutures
• Pessaries
• Robotic Systems

By Treatment:

• Surgical
• PFMT

By Application:

• Cystocele
• Uterine Prolapse

By End User:

• Hospitals
• ASCs

Value-Creating Segments and Growth Pockets

Surgical treatment currently dominates the market due to the high volume of moderate to severe prolapse cases requiring anatomical repair. Within products, sutures and synthetic mesh remain foundational to reconstructive procedures, although robotic systems are expected to witness accelerated growth driven by minimally invasive surgery trends.

While cystocele represents a significant share owing to its prevalence, uterine prolapse cases are projected to grow steadily with increasing awareness and diagnosis rates. Hospitals maintain leadership in procedural volumes due to specialized surgical infrastructure; however, ASCs are anticipated to expand at a faster pace as minimally invasive techniques become standardized and cost pressures intensify.

PFMT, although representing a smaller revenue share today, constitutes a promising growth pocket as early-stage management gains prominence and digital therapy solutions improve accessibility.

Regional Market Assessment

North America

North America leads the market, supported by advanced surgical infrastructure, high awareness of pelvic health, and established reimbursement mechanisms. Strong adoption of robotic-assisted surgery further reinforces regional leadership.

Europe

Europe demonstrates stable growth driven by aging demographics and well-developed public healthcare systems. Regulatory reforms related to mesh products have influenced product mix and accelerated innovation in alternative repair methods.

Asia Pacific

Asia Pacific is poised for accelerated growth due to expanding healthcare access, rising awareness of women's health issues, and increasing investment in minimally invasive surgical technologies. Growing urbanization and improving specialist availability support market expansion.

LAMEA

The LAMEA region exhibits gradual adoption, influenced by improving healthcare infrastructure and rising female health awareness. Market penetration remains uneven, offering long-term potential as access to gynecological services expands.

Recent Developments

• February 2024: Introduction of an advanced robotic platform optimized for gynecological reconstructive surgery, enhancing precision in POP repair procedures.
• August 2023: Launch of next-generation biocompatible suture materials designed to improve tissue integration and reduce complication rates.
• May 2023: Expansion of pelvic floor rehabilitation programs integrated with digital physiotherapy tools to enhance PFMT adherence.

Critical Business Questions Addressed

• What is the projected growth trajectory of the POP treatment and management market through 2035?

The report evaluates a steady 6.60% CAGR supported by demographic shifts and surgical innovation.

• Which treatment modality will generate the highest incremental value?

Surgical approaches dominate revenue, while robotic-assisted procedures and PFMT represent emerging growth avenues.

• How are regulatory developments influencing product strategy?

Increased oversight of mesh products is driving innovation in safer biomaterials and alternative techniques.

• Which end-user settings offer the strongest expansion potential?

Hospitals lead today, but ASCs are positioned for faster procedural growth due to cost efficiencies.

• What strategic investments are essential for competitive differentiation?

Advancements in robotic systems, biomaterials, and integrated therapy models are critical to sustaining market leadership.

Beyond the Forecast

The POP treatment and management market is transitioning toward minimally invasive, safety-driven, and patient-centric care models. Long-term value creation will depend on technological precision, material innovation, and integration of conservative therapies. Market participants that align clinical efficacy with regulatory compliance and cost efficiency will shape the next phase of sustainable growth in pelvic health management.

Table of Contents

Chapter 1. Global POP Treatment and Management / Pelvic Organ Prolapse Market Report Scope & Methodology

• 1.1. Market Definition
• 1.2. Market Segmentation
• 1.3. Research Assumption
  • 1.3.1. Inclusion & Exclusion
  • 1.3.2. Limitations
• 1.4. Research Objective
• 1.5. Research Methodology
  • 1.5.1. Forecast Model
  • 1.5.2. Desk Research
  • 1.5.3. Top Down and Bottom-Up Approach
• 1.6. Research Attributes
• 1.7. Years Considered for the Study

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Strategic Insights
• 2.3. Top Findings
• 2.4. CEO/CXO Standpoint
• 2.5. ESG Analysis

Chapter 3. Global POP Treatment and Management / Pelvic Organ Prolapse Market Forces Analysis

• 3.1. Market Forces Shaping The Global POP Treatment and Management / Pelvic Organ Prolapse Market (2024-2035)
• 3.2. Drivers
  • 3.2.1. Rising Prevalence of Pelvic Floor Disorders
  • 3.2.2. Technological Advancements in Minimally Invasive Surgery
  • 3.2.3. Regulatory Oversight and Safety Concerns
  • 3.2.4. Growing Acceptance of Conservative Therapies
• 3.3. Restraints
  • 3.3.1. Healthcare Infrastructure and Reimbursement Dynamics
• 3.4. Opportunities
  • 3.4.1. Robotic-Assisted Surgical Expansion
  • 3.4.2. Next-Generation Biomaterials and Mesh Alternatives

Chapter 4. Global POP Treatment and Management / Pelvic Organ Prolapse Industry Analysis

• 4.1. Porter's 5 Forces Model
• 4.2. Porter's 5 Force Forecast Model (2024-2035)
• 4.3. PESTEL Analysis
• 4.4. Macroeconomic Industry Trends
  • 4.4.1. Parent Market Trends
  • 4.4.2. GDP Trends & Forecasts
• 4.5. Value Chain Analysis
• 4.6. Top Investment Trends & Forecasts
• 4.7. Top Winning Strategies (2025)
• 4.8. Market Share Analysis (2024-2025)
• 4.9. Pricing Analysis
• 4.10. Investment & Funding Scenario
• 4.11. Impact of Geopolitical & Trade Policy Volatility on the Market

Chapter 5. AI Adoption Trends and Market Influence

• 5.1. AI Readiness Index
• 5.2. Key Emerging Technologies
• 5.3. Patent Analysis
• 5.4. Top Case Studies

Chapter 6. Global POP Treatment and Management / Pelvic Organ Prolapse Market Size & Forecasts by Product 2025-2035

• 6.1. Market Overview
• 6.2. Global POP Treatment and Management / Pelvic Organ Prolapse Market Performance - Potential Analysis (2025)
• 6.3. Synthetic Mesh
  • 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 6.3.2. Market size analysis, by region, 2025-2035
• 6.4. Sutures
  • 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 6.4.2. Market size analysis, by region, 2025-2035
• 6.5. Pessaries
  • 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 6.5.2. Market size analysis, by region, 2025-2035
• 6.6. Robotic Systems
  • 6.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 6.6.2. Market size analysis, by region, 2025-2035

Chapter 7. Global POP Treatment and Management / Pelvic Organ Prolapse Market Size & Forecasts by Treatment 2025-2035

• 7.1. Market Overview
• 7.2. Global POP Treatment and Management / Pelvic Organ Prolapse Market Performance - Potential Analysis (2025)
• 7.3. Surgical
  • 7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 7.3.2. Market size analysis, by region, 2025-2035
• 7.4. PFMT
  • 7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 7.4.2. Market size analysis, by region, 2025-2035

Chapter 8. Global POP Treatment and Management / Pelvic Organ Prolapse Market Size & Forecasts by Application 2025-2035

• 8.1. Market Overview
• 8.2. Global POP Treatment and Management / Pelvic Organ Prolapse Market Performance - Potential Analysis (2025)
• 8.3. Cystocele
  • 8.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 8.3.2. Market size analysis, by region, 2025-2035
• 8.4. Uterine Prolapse
  • 8.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 8.4.2. Market size analysis, by region, 2025-2035

Chapter 9. Global POP Treatment and Management / Pelvic Organ Prolapse Market Size & Forecasts by End User 2025-2035

• 9.1. Market Overview
• 9.2. Global POP Treatment and Management / Pelvic Organ Prolapse Market Performance - Potential Analysis (2025)
• 9.3. Hospitals
  • 9.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 9.3.2. Market size analysis, by region, 2025-2035
• 9.4. ASCS
  • 9.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 9.4.2. Market size analysis, by region, 2025-2035

Chapter 10. Global POP Treatment and Management / Pelvic Organ Prolapse Market Size & Forecasts by Region 2025-2035

• 10.1. Growth POP Treatment and Management / Pelvic Organ Prolapse Market, Regional Market Snapshot
• 10.2. Top Leading & Emerging Countries
• 10.3. North America POP Treatment and Management / Pelvic Organ Prolapse Market
  • 10.3.1. U.S. POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.3.1.1. Product breakdown size & forecasts, 2025-2035
    • 10.3.1.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.3.1.3. Application breakdown size & forecasts, 2025-2035
    • 10.3.1.4. End User breakdown size & forecasts, 2025-2035
  • 10.3.2. Canada POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.3.2.1. Product breakdown size & forecasts, 2025-2035
    • 10.3.2.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.3.2.3. Application breakdown size & forecasts, 2025-2035
    • 10.3.2.4. End User breakdown size & forecasts, 2025-2035
• 10.4. Europe POP Treatment and Management / Pelvic Organ Prolapse Market
  • 10.4.1. UK POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.4.1.1. Product breakdown size & forecasts, 2025-2035
    • 10.4.1.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.4.1.3. Application breakdown size & forecasts, 2025-2035
    • 10.4.1.4. End User breakdown size & forecasts, 2025-2035
  • 10.4.2. Germany POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.4.2.1. Product breakdown size & forecasts, 2025-2035
    • 10.4.2.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.4.2.3. Application breakdown size & forecasts, 2025-2035
    • 10.4.2.4. End User breakdown size & forecasts, 2025-2035
  • 10.4.3. France POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.4.3.1. Product breakdown size & forecasts, 2025-2035
    • 10.4.3.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.4.3.3. Application breakdown size & forecasts, 2025-2035
    • 10.4.3.4. End User breakdown size & forecasts, 2025-2035
  • 10.4.4. Spain POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.4.4.1. Product breakdown size & forecasts, 2025-2035
    • 10.4.4.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.4.4.3. Application breakdown size & forecasts, 2025-2035
    • 10.4.4.4. End User breakdown size & forecasts, 2025-2035
  • 10.4.5. Italy POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.4.5.1. Product breakdown size & forecasts, 2025-2035
    • 10.4.5.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.4.5.3. Application breakdown size & forecasts, 2025-2035
    • 10.4.5.4. End User breakdown size & forecasts, 2025-2035
  • 10.4.6. Rest of Europe POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.4.6.1. Product breakdown size & forecasts, 2025-2035
    • 10.4.6.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.4.6.3. Application breakdown size & forecasts, 2025-2035
    • 10.4.6.4. End User breakdown size & forecasts, 2025-2035
• 10.5. Asia Pacific POP Treatment and Management / Pelvic Organ Prolapse Market
  • 10.5.1. China POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.5.1.1. Product breakdown size & forecasts, 2025-2035
    • 10.5.1.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.5.1.3. Application breakdown size & forecasts, 2025-2035
    • 10.5.1.4. End User breakdown size & forecasts, 2025-2035
  • 10.5.2. India POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.5.2.1. Product breakdown size & forecasts, 2025-2035
    • 10.5.2.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.5.2.3. Application breakdown size & forecasts, 2025-2035
    • 10.5.2.4. End User breakdown size & forecasts, 2025-2035
  • 10.5.3. Japan POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.5.3.1. Product breakdown size & forecasts, 2025-2035
    • 10.5.3.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.5.3.3. Application breakdown size & forecasts, 2025-2035
    • 10.5.3.4. End User breakdown size & forecasts, 2025-2035
  • 10.5.4. Australia POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.5.4.1. Product breakdown size & forecasts, 2025-2035
    • 10.5.4.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.5.4.3. Application breakdown size & forecasts, 2025-2035
    • 10.5.4.4. End User breakdown size & forecasts, 2025-2035
  • 10.5.5. South Korea POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.5.5.1. Product breakdown size & forecasts, 2025-2035
    • 10.5.5.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.5.5.3. Application breakdown size & forecasts, 2025-2035
    • 10.5.5.4. End User breakdown size & forecasts, 2025-2035
  • 10.5.6. Rest of APAC POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.5.6.1. Product breakdown size & forecasts, 2025-2035
    • 10.5.6.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.5.6.3. Application breakdown size & forecasts, 2025-2035
    • 10.5.6.4. End User breakdown size & forecasts, 2025-2035
• 10.6. Latin America POP Treatment and Management / Pelvic Organ Prolapse Market
  • 10.6.1. Brazil POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.6.1.1. Product breakdown size & forecasts, 2025-2035
    • 10.6.1.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.6.1.3. Application breakdown size & forecasts, 2025-2035
    • 10.6.1.4. End User breakdown size & forecasts, 2025-2035
  • 10.6.2. Mexico POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.6.2.1. Product breakdown size & forecasts, 2025-2035
    • 10.6.2.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.6.2.3. Application breakdown size & forecasts, 2025-2035
    • 10.6.2.4. End User breakdown size & forecasts, 2025-2035
• 10.7. Middle East and Africa POP Treatment and Management / Pelvic Organ Prolapse Market
  • 10.7.1. UAE POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.7.1.1. Product breakdown size & forecasts, 2025-2035
    • 10.7.1.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.7.1.3. Application breakdown size & forecasts, 2025-2035
    • 10.7.1.4. End User breakdown size & forecasts, 2025-2035
  • 10.7.2. Saudi Arabia (KSA) POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.7.2.1. Product breakdown size & forecasts, 2025-2035
    • 10.7.2.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.7.2.3. Application breakdown size & forecasts, 2025-2035
    • 10.7.2.4. End User breakdown size & forecasts, 2025-2035
  • 10.7.3. South Africa POP Treatment and Management / Pelvic Organ Prolapse Market
    • 10.7.3.1. Product breakdown size & forecasts, 2025-2035
    • 10.7.3.2. Treatment breakdown size & forecasts, 2025-2035
    • 10.7.3.3. Application breakdown size & forecasts, 2025-2035
    • 10.7.3.4. End User breakdown size & forecasts, 2025-2035

Chapter 11. Competitive Intelligence

• 11.1. Top Market Strategies
• 11.2. Boston Scientific Corporation (US)
  • 11.2.1. Company Overview
  • 11.2.2. Key Executives
  • 11.2.3. Company Snapshot
  • 11.2.4. Financial Performance (Subject to Data Availability)
  • 11.2.5. Product/Services Port
  • 11.2.6. Recent Development
  • 11.2.7. Market Strategies
  • 11.2.8. SWOT Analysis
• 11.3. Coloplast Group (Denmark)
• 11.4. Intuitive Surgical Operations, Inc. (US)
• 11.5. CooperCompanies (US)
• 11.6. Johnson & Johnson (US)
• 11.7. GE HealthCare (US)
• 11.8. Integra LifeSciences Corporation (US)
• 11.9. B. Braun SE (Germany)
• 11.10. pfm medical gmbh (Germany)